NCT00372086

Rosiglitazone and Insulin in T1DM Adolescents

The Addition of Rosiglitazone to Insulin in Adolescents With Type 1 Diabetes and Poor Glycaemic Control: a Randomized, Placebo Controlled Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 32 (planned)
• Sponsor: The University of New South Wales · Academic / Other
• Sex: All
• Age: 10 Years – 18 Years
• Healthy volunteers: —

Summary

Type 1 Diabetes is the most common life-long disorder with onset in childhood. Patients need insulin injections, blood sugar monitoring several times each day, and adhere to a strict diet. Adequate control of blood glucose is essential to prevent long term kidney and eye complications that result in kidney failure and blindness. Adolescence is a time when diabetes is difficult to control, due in part to high growth hormone levels causing insulin resistance ( a state where the body does not respond as strongly to insulin). This study will test whether treatment with rosiglitazone (an oral medication used frequently in type 2 diabetes) will reduce the insulin resistance of adolescence and improve the control of type 1 diabetes during puberty.

Conditions

• Type 1 Diabetes
• Puberty: >Tanner 2 Breast Development or Testis >4ml

Interventions

Type	Name	Description
DRUG	Rosiglitazone

Timeline

• Start date: 2003-08-01
• Completion: 2005-09-01
• First posted: 2006-09-06
• Last updated: 2006-09-06

Locations

1 site across 1 country: Australia